A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Azacitidine (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 31 May 2017 Planned End Date changed from 14 Apr 2017 to 12 Oct 2017.
- 12 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
- 12 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.